Zydus Cadila gets USFDA nod to market breast cancer drug

Drug firm Zydus Cadila today said it has received final approval from the United States Food and Drug Administration (USFDA) to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base).
It (Tamoxifen Citrate Tablets USP) will be manufactured at the group's formulations manufacturing facility at SEZ in Ahmedabad, the company said in a BSE filing.
The drug is indicated to treat breast cancer, the company said in the filing.
The group now has more than 165 approvals, it added.